Polypharmacy and Falls Risk in Dementia Care: Reducing Harm Through Structured Medicines Governance
Polypharmacy is one of the most persistent and under-recognised drivers of falls and deterioration in dementia care. Sedatives, antihypertensives, anticholinergics and PRN medications can compound frailty and impair balance. Effective providers embed structured review within dementia medicines, falls and frailty systems and align prescribing oversight to coherent dementia service models. Commissioners and inspectors expect clear evidence that medicines are reviewed regularly, deprescribing is considered proactively and prescribing decisions are linked to mobility and safety outcomes.
Understanding cumulative medicines burden
In dementia care, risk often stems from cumulative impact rather than a single drug. Mild sedation combined with postural hypotension and dehydration can significantly increase falls risk. Governance systems must therefore move beyond basic MAR accuracy and address clinical impact.
Operational example 1: Sedative burden and night-time falls
Context: A resident experiences two unwitnessed night-time falls within one month.
Support approach: Medicines review identifies regular hypnotic use and frequent PRN anxiolytics.
Day-to-day delivery detail: Gradual dose reduction agreed with GP. Non-pharmacological sleep strategies introduced, including consistent bedtime routine and environmental adjustments. Staff document sleep quality and mobility daily.
How effectiveness is evidenced: Night-time falls cease, PRN usage decreases by 50% and sleep stabilises without increased distress.
Operational example 2: Antihypertensive timing and postural drops
Context: Recurrent dizziness reported during morning transfers.
Support approach: Orthostatic blood pressure monitoring undertaken for five days.
Day-to-day delivery detail: Prescriber adjusts dose timing to later in the day. Staff delay mobilisation briefly post-dose and reinforce hydration routines.
How effectiveness is evidenced: Reduced postural hypotension episodes and improved transfer confidence recorded in mobility logs.
Operational example 3: Anticholinergic load and confusion
Context: Increasing confusion and unsteadiness noted after new bladder medication introduced.
Support approach: Pharmacist consultation reviews anticholinergic burden.
Day-to-day delivery detail: Medication discontinued following review. Staff monitor cognition and balance daily for two weeks.
How effectiveness is evidenced: Improved alertness, no further near-miss falls and documented cognitive recovery.
Commissioner expectation: demonstrable medicines optimisation
Commissioner expectation: Commissioners expect evidence of regular multidisciplinary medicines review, pharmacist involvement and measurable reduction in medicines-related incidents.
Regulator / Inspector expectation (CQC): safe and well-led systems
Regulator / Inspector expectation (CQC): Inspectors assess whether prescribing decisions are reviewed proactively, linked to risk assessment and clearly documented in care planning and governance meetings.
Embedding structured medicines governance
Quarterly polypharmacy audits, PRN trend analysis and integration with falls dashboards create inspection-ready oversight. When services link medicines optimisation directly to mobility and frailty outcomes, they reduce avoidable harm while preserving dignity and independence.